Baseline characteristics
| Characteristicss . | Total (N = 52) . |
|---|---|
| Median age (range), y | 29 (13-54) |
| Sex, male | 34 (69%) |
| Disease stage at diagnosis | |
| II | 10 (19%) |
| III | 12 (23%) |
| IV | 30 (58%) |
| Extranodal disease at enrollment | 26 (50%) |
| Number of previous systemic therapy | |
| Median (range) | 5 (2-12) |
| ≥3 | 50 (96%) |
| Previous ASCT | 12 (23%) |
| Transplant ineligible | 40 (77%) |
| Previous BV | 5 (10%) |
| Last systemic therapy before enrollment | |
| DP therapy | 44 (85%) |
| Disease progression on active treatment | 42 (81%) |
| Disease relapse after DP discontinuation | 2 (4%) |
| Non-DP therapy | 8 (15%) |
| Previous DP therapy | |
| Median cycles (range) | 12 (4-44) |
| ORR (95% CI) | 77% (63-87) |
| CR rate (95% CI) | 29% (17-43) |
| Median PFS (mo) | 13.6 |
| Characteristicss . | Total (N = 52) . |
|---|---|
| Median age (range), y | 29 (13-54) |
| Sex, male | 34 (69%) |
| Disease stage at diagnosis | |
| II | 10 (19%) |
| III | 12 (23%) |
| IV | 30 (58%) |
| Extranodal disease at enrollment | 26 (50%) |
| Number of previous systemic therapy | |
| Median (range) | 5 (2-12) |
| ≥3 | 50 (96%) |
| Previous ASCT | 12 (23%) |
| Transplant ineligible | 40 (77%) |
| Previous BV | 5 (10%) |
| Last systemic therapy before enrollment | |
| DP therapy | 44 (85%) |
| Disease progression on active treatment | 42 (81%) |
| Disease relapse after DP discontinuation | 2 (4%) |
| Non-DP therapy | 8 (15%) |
| Previous DP therapy | |
| Median cycles (range) | 12 (4-44) |
| ORR (95% CI) | 77% (63-87) |
| CR rate (95% CI) | 29% (17-43) |
| Median PFS (mo) | 13.6 |